Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression

Zanjani, Leili Saeednejad; Razmi, Mahdieh; Fattahi, Fahimeh; Kalantari, Elham; Abolhasani, Maryam; Saki, Sima; Madjd, Zahra; Mohsenzadegan, Monireh

doi:10.1007/s00432-021-03859-1

Cited by 4 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was achieved by decreasing the stability of NCID through affecting its ubiquitination modifications [26]. MAGE-A2 was highly expressed in cancers such as glioma, lung cancer and embryonal carcinoma and is closely associated with poor patient prognosis [27][28][29]. Hideki Uj and colleagues found that MAGE-A2 played a prognostic role in lung cancer and may promote tumor by regulating the p53 signaling pathway [28].…”

Section: Discussionmentioning

confidence: 99%

MAGE-A11 is a potential prognostic biomarker and immunotherapeutic target in gastric cancer

Wang,

Yu,

et al. 2024

Aging

View full text Add to dashboard Cite

Gastric cancer poses a serious threat to human health and affects the digestive system. The lack of early symptoms and a dearth of effective identification methods make diagnosis difficult, with many patients only receiving a definitive diagnosis at a malignant stage, causing them to miss out on optimal therapeutic interventions. Melanoma-associated antigen-A (MAGE-A) is part of the MAGE family and falls under the cancer/testis antigen (CTA) category. The MAGE-A subfamily plays a significant role in tumorigenesis, proliferation and migration. The expression, prognosis and function of MAGE-A family members in GC, however, remain unclear. Our research and screening have shown that MAGE-A11 was highly expressed in GC tissues and was associated with poor patient prognosis. Additionally, MAGE-A11 functioned as an independent prognostic factor in GC through Cox regression analysis, and its expression showed significant correlation with both tumour immune cell infiltration and responsiveness to immunotherapy. Our data further indicated that MAGE-A11 regulated GC cell proliferation and migration. Subsequently, our findings propose that MAGE-A11 may operate as a prognostic factor, having potential as an immunotherapy target for GC.

show abstract

Section: Discussionmentioning

confidence: 99%

MAGE-A11 is a potential prognostic biomarker and immunotherapeutic target in gastric cancer

Wang,

Yu,

et al. 2024

Aging

View full text Add to dashboard Cite

show abstract

“…The TMA blocks were then serially sectioned to a thickness of 4 m and scored individually. Finally, the median of the 3 cores of each sample was calculated as the final score 30 . It is important to note that in addition to tumor tissue samples, each TMA block also contained adjacent normal tissue specimens to facilitate the comparison of protein expression levels.…”

Section: Methodsmentioning

confidence: 99%

Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients

Sadeghipour,

Taha,

Shariat Zadeh

et al. 2024

Applied Immunohistochemistry &Amp; Molecular Morphology

Self Cite

View full text Add to dashboard Cite

Introduction: Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults. Although studies regarding the association between the expression of Ki-67, CD10, BCL6, and MUM1 proteins, as well as c-MYC amplification and EBV status with clinicopathologic characteristics have rapidly progressed, their co-expression and prognostic role remain unsatisfactory. Therefore, this study aimed to investigate the association between the expression of all markers and clinicopathologic features and their prognostic value in DLBCL. Also, the co-expression of markers was investigated. Methods: The protein expression levels and prognostic significance of Ki-67, CD10, BCL6, and MUM1 were investigated with clinical follow-up in a total of 53 DLBCL specimens (including germinal center B [GCB] and activated B cell [ABC] subtypes) as well as adjacent normal samples using immunohistochemistry (IHC). Besides, the clinical significance and prognostic value of c-MYC and EBV status were also evaluated through chromogenic in situ hybridization (CISH), and their correlation with other markers was also assessed. Results: The results demonstrated a positive correlation between CD10 and BCL6 expression, with both markers being associated with the GCB subtype (P<0.001 and P=0.001, respectively). Besides, we observe a statistically significant association between MUM1 protein expression and clinicopathologic type (P<0.005) as well as a positive association between c-MYC and recurrence (P=0.028). Our survival analysis showed that patients who had responded to R-CHOP treatment had better overall survival (OS) and progression-free survival (PFS) than those who did not. Conclusion: Collectively, this study's results add these markers' value to the existing clinical understanding of DLBCL. However, further investigations are needed to explore markers' prognostic and biological roles in DLBCL patients.

show abstract

Nuclear Expression of Dynamin 2 Is Associated With Tumor Aggressiveness in Bladder Cancer Patients: A Bioinformatics and Experimental Approach

Razmi,

Saeednejad Zanjani,

Rahimi

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundDynamin 2 (DNM2) is aberrantly expressed in different malignancies and exerts a function in tumor progression.AimsThis study, for the first time, aimed to evaluate the clinical and prognostic value of DNM2 in the pathophysiology of bladder cancer using bioinformatics analysis and experimental evaluation.Methods and ResultsWe analyzed gene expression of DNM2 in bladder tumor by GEPIA2 and GENT2 platforms. Cluster subnetworks were recognized from the protein–protein interaction (PPI) network using the MCODE plugin to screen the key genes. Subsequently, the pathway enrichment analysis was evaluated. Then, the immunohistochemical examination was conducted on 209 paraffin‐embedded bladder cancer samples to determine the expression pattern and clinical importance of DNM2. Our data mining findings demonstrated dysregulation of DNM2 gene expression in bladder cancer. The results of pathway and PPI network analyses indicated that DNM2 might be involved in the development of bladder cancer by influencing various signaling pathways. Our IHC results represented remarkably higher DNM2 expression in bladder tumor samples compared to normal tissue samples adjacent to tumor. A statistically significant association was identified between DNM2 expression in the nucleus and higher histological grade (p = 0.026), advanced pT stage (p = 0.016), muscular invasion (p = 0.007), tumor recurrence (p = 0.030), and distant metastasis (p < 0.001). Moreover, the nuclear DNM2 expression was observed to have prognostic significance for disease‐specific survival (DSS) using a log‐rank test (p = 0.028).ConclusionThese findings suggest that nuclear DNM2 expression could be a putative indicator of bladder tumor progression owing to its association with elevated cancer aggressiveness.

show abstract

Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression

Cited by 4 publications

References 51 publications

MAGE-A11 is a potential prognostic biomarker and immunotherapeutic target in gastric cancer

MAGE-A11 is a potential prognostic biomarker and immunotherapeutic target in gastric cancer

Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients

Nuclear Expression of Dynamin 2 Is Associated With Tumor Aggressiveness in Bladder Cancer Patients: A Bioinformatics and Experimental Approach

Contact Info

Product

Resources

About